Practice question

Answer the question and get instant feedback.

Moderateadding a GLP‑1 RA with proven CV benefit reduces eventsASCVD"ada standards of care (2025): pharmacologic approaches to glycaemic treatment"

A 61-year-old with diabetes and ASCVD has A1c 7.8% on metformin and SGLT2 inhibitor. To further reduce CV events per ADA 2025

Educational content. Not a substitute for clinical judgement or local policy.